Regencell Bioscience Holdings Ltd Dossier
Qualitative Analysis
Business overview
Regencell Bioscience Holdings Limited (NASDAQ: RGC) is an early-stage, clinical-phase bioscience company incorporated in the Cayman Islands and operating primarily out of Hong Kong. Founded in 2014, the company focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) formulations for neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). Additionally, the company has explored treatments for infectious diseases affecting the immune system, such as COVID-19. Regencell's therapeutic candidates are natural, orally administered liquid formulations based on the Sik-Kee Au TCM Brain Theory®, which posits that neurocognitive disorders stem from inadequate blood and nutrient flow to specific brain regions. The company operates as a pre-revenue research and development shop with no approved or salable products.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Research, development, and clinical evaluation of three standardized liquid-based Traditional Chinese Medicine (TCM) formulae candidates targeting mild, moderate, and severe ADHD and ASD patients, derived from the proprietary 'Sik-Kee Au TCM Brain Theory™'.
Expected impact: Establish clinical efficacy and safety profiles to support future proprietary Chinese medicine (pCm) registration applications.
Securing operational runway through strategic equity offerings, including a $20 million private placement in May 2026 and the establishment of an At-The-Market (ATM) sales agreement of up to $500 million in March 2026.
Expected impact: Addresses substantial doubt regarding the company's ability to continue as a going concern by extending cash runway into 2027.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides Regencell with exclusive global rights and ownership of all TCM formulae and associated intellectual property developed by the practitioner (the father of the CEO) for neurocognitive disorders.
Terms: Regencell is required to donate 3.0% of net revenue generated from the commercialization of the TCM formulae to charitable institutions chosen by the practitioner, and cover all reasonable research and development expenses incurred by him.